research The Burden of Alopecia Areata and Management with Baricitinib in the United Arab Emirates: A Narrative Review
Baricitinib is a promising treatment for alopecia areata in the UAE, but there are challenges with data and access.
Search
for
Sort by
Research
690-720 / 1000+ results research 783 Influence of TNF gene polymorphism in patients with acute and fulminnant hepatitis
research When to expect scalp hair regrowth during treatment of severe alopecia areata with baricitinib: insights from trajectories analyses of patients enrolled in two phase III trials
Hair regrowth from severe alopecia areata treatment with baricitinib can vary, with faster results in those with shorter hair loss duration.
research A case of bullous pemphigoid in a malignant melanoma patient following an increased Th2/Th1 ratio in peripheral blood cells after nivolumab treatment
Combining hair transplantation with PRP is more effective for treating hair loss than hair transplantation alone.
research Baricitinib Withdrawal and Retreatment in Patients With Severe Alopecia Areata
Continuous baricitinib is needed to keep hair regrowth in severe alopecia areata.
research Upadacitinib for the Treatment of Systemic Immune Co-Morbidity in One Case: Alopecia Areata, Vitiligo, Ankylosing Spondylitis, and Allergic Rhinitis-Asthma – Multifaceted Control
Upadacitinib improved multiple immune-related conditions in one patient.
research Integrated Safety Analysis of Ritlecitinib in Adolescent Patients with Alopecia Areata from the Randomized, Placebo-Controlled ALLEGRO Phase 2b/3 and Ongoing Open-Label Phase 3 ALLEGRO-LT Studies
research 139 Anti-BCC efficacy of a topical hedgehog inhibitor without adverse effects in BCNS patients in a phase 2 randomized controlled trial
Topical patidegib gel effectively treats basal cell carcinoma in Gorlin syndrome patients without causing the side effects seen with oral treatments.
research Baricitinib-Induced Remission of Alopecia Universalis in a Child with NFKB2-Associated Immune Dysregulation
research BH09 Patient experience of off-label Janus kinase inhibitor use for alopecia areata in a cohort of 34 patients from a single UK practitioner: exploring changing trends in healthcare provision and access to drug treatments
Patients with alopecia areata face challenges accessing Janus kinase inhibitors, but some see positive results.
research 49690 Long-term efficacy of baricitinib in alopecia areata: 3-year results from BRAVE-AA1 and BRAVE-AA2
Baricitinib maintains significant hair regrowth in severe alopecia areata over three years.
research Lyophilized growth factor intralesional injection in female pattern hair loss: A clinical and trichoscopic study
Injections improve hair growth, density, and thickness in women safely.
research Parenteral and Oral Cyproterone Acetate Treatment in Severe Hirsutism
Cyproterone acetate implants were more effective at reducing facial hair and improving skin in severe hirsutism than oral treatment.
research Intensive immunosuppression in patients with disseminated sclerosis. I. Clinical response.
Intensive immunosuppression can reduce relapse rates in multiple sclerosis patients, despite some side effects.
research Successful plasmapheresis and immunoglobulin treatment for severe lipid storage myopathy: Doing the right thing for the wrong reason
Correct diagnosis and treatment are crucial for effective management of lipid storage myopathies.
research Extensive alopecia areata is reversed by IL-12/IL-23p40 cytokine antagonism
Blocking IL-12/IL-23p40 helped reverse severe hair loss in patients.
research Finasteride versus cyproterone acetate-estrogen regimens in the treatment of hirsutism
Finasteride and CPA-EE2 equally reduce hirsutism, but affect hormone levels differently.
research Post-marketing safety signals of four JAK inhibitors for alopecia areata: an indication-restricted FAERS pharmacovigilance study
JAK inhibitors for alopecia areata have different safety risks, requiring specific monitoring for each drug.
research 43046 Outcomes of Down-Titration in Patients with Severe Scalp Alopecia Areata Treated with Baricitinib 4 Mg: Week 104 Data from BRAVE-AA2
Reducing the dose of Baricitinib to 2mg led to a loss of hair regrowth benefits in nearly half of the patients by Week-104.
research Budget impact analysis of baricitinib for treatment of alopecia areata: A Saudi hospital perspective
Adding baricitinib will increase costs but offers more treatment options for alopecia areata.
research Reporte de caso: alopecia areata universal tratada exitosamente con baricitinib
Baricitinib successfully treated severe hair loss.
research Antipsoriatic Activity of a New Synthetic Retinoid
The new synthetic retinoid RO 13-6298 effectively treated severe psoriasis at low doses with manageable side effects.
research Performance of an interferon-γ release assay-based test for cell-mediated immunity to SARS-CoV-2
The IGRA test effectively detects past SARS-CoV-2 exposure, especially using nucleocapsid peptides.
research FINASTERIDE (PLUS ORAL CONTRACEPTIVE PILL) VS METFORMIN IN TREATMENT OF POLYCYSTIC OVARY SYNDROME-RELATED INFERTILITY: A PROSPECTIVE RANDOMIZED TRIAL
research REVERSED SEQUENTIAL THERAPY OF HIRSUTISM USING CYPROTERONE ACETATE
Reversed sequential therapy with cyproterone acetate was effective for treating women with hirsutism and related conditions.
research Baseline methotrexate does not impact the incidence of infliximab infusion reactions: Results from a Canadian real-world treatment registry
Clofazimine effectively treated ashy dermatosis in a patient.
research Ruxolitinib for the treatment of severe alopecia areata
Ruxolitinib can help regrow hair in severe alopecia areata.
research The development of oral hairy leukoplakia during JAK inhibitor baricitinib therapy
A man developed oral hairy leukoplakia while on baricitinib, a medication for alopecia and arthritis, and doctors should watch for such side effects.
research Intravaginal Testosterone Improves Sexual Satisfaction and Vaginal Symptoms Associated With Aromatase Inhibitors
Intravaginal testosterone cream improves sexual satisfaction and reduces vaginal discomfort in postmenopausal women on breast cancer treatment without affecting hormone levels.
research Anlotinib or Bevacizumab Combined with Taxane/Capecitabine for the Second-Line or Subsequent Treatment of HER-2 Negative Metastatic Breast Cancer: A Retrospective Cohort Study
Anlotinib combined with taxane/capecitabine is more effective than bevacizumab for treating HER-2 negative metastatic breast cancer.